...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction.
【24h】

Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction.

机译:具有移植后淋巴增生性疾病发展风险的患者:血浆与外周血单核细胞通过实时定量聚合酶链反应用于量化Epstein-Barr病毒载量。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Early diagnosis of Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorder (PTLD) is required to detect a stage of disease that is more likely to respond to treatment. Elevated levels of EBV DNA were found in peripheral blood of patients at the onset of PTLD. METHODS: To compare plasma and peripheral blood mononuclear cells (PBMCs) as material for real-time quantitative polymerase chain reaction (RQ-PCR) measurement of Epstein-Barr viral load, we used two sets of primers and probes specific for the BAM HI-K or BAM HI-W region of the EBV genome. RESULTS: Patients with PTLD had a median viral load of 19,200 EBV genomes/microg DNA (n=9) or 3,225 EBV genomes/100 microl plasma (n=5), being significantly higher compared with immunosuppressed patients with primary (n=9) or reactivated (n=20) EBV infection or immunosuppressed patients without serological signs of active EBV infection (n=67) (P<0.001). Hence, a value of greater than 5,000 EBV genomes/microg PBMC DNA was considered as a diagnostic parameter for PTLD with a sensitivity and specificity of 1.00 or 0.89, respectively. When plasma was analyzed, however, a value of greater than 1,000 EBV genomes/100 microl plasma had both a sensitivity and specificity of 1.00 for the diagnosis of PTLD. During remission of PTLD, viral load was more effectively cleared in plasma compared with PBMCs. In plasma of nonimmunosuppressed individuals, even a qualitative detection of EBV-related sequences was sensitive and specific for the diagnosis of primary EBV infection, whereas for analysis of PBMC DNA a quantitative parameter had to be considered to differentiate healthy individuals (< 100 EBV genomes/microg PBMC DNA) from patients with primary EBV infection (>100 EBV genomes/microg PBMC DNA). CONCLUSION: Although both PBMCs and plasma were useful as material for EBV-specific RQ-PCR in immunosuppressed patients and nonimmunosuppressed individuals, the specificity of analysis seemed to be higher if plasma was taken for analysis.
机译:背景:需要早期诊断与爱泼斯坦巴尔病毒(EBV)相关的移植后淋巴组织增生性疾病(PTLD),以检测更可能对治疗产生反应的疾病阶段。在PTLD发作时,患者外周血中EBV DNA水平升高。方法:为了比较血浆和外周血单个核细胞(PBMC)作为实时定量聚合酶链反应(RQ-PCR)测量爱泼斯坦-巴尔病毒载量的材料,我们使用了两组针对BAM HI-的特异性引物和探针EBV基因组的K或BAM HI-W区。结果:PTLD患者的病毒载量中位数为19,200 EBV基因组/微克DNA(n = 9)或3,225 EBV基因组/ 100微升血浆(n = 5),比免疫抑制的原发性患者(n = 9)高得多或重新激活(n = 20)的EBV感染或没有活动性EBV感染的血清学指标的免疫抑制患者(n = 67)(P <0.001)。因此,大于5,000 EBV基因组/微克PBMC DNA的值被认为是PTLD的诊断参数,其灵敏度和特异性分别为1.00或0.89。但是,当分析血浆时,大于1,000 EBV基因组/ 100微升血浆的值对PTLD的诊断灵敏度和特异性均为1.00。与PBMC相比,在PTLD缓解期间,血浆中的病毒载量被更有效地清除。在非免疫抑制个体的血浆中,即使对EBV相关序列进行定性检测对于原发性EBV感染的诊断也是敏感和特异的,而对于PBMC DNA的分析,则必须考虑使用定量参数来区分健康个体(<100 EBV基因组/原发性EBV感染的患者(> 100 EBV基因组/ microg PBMC DNA)。结论:尽管PBMC和血浆均可用作免疫抑制患者和非免疫抑制患者的EBV特异性RQ-PCR的材料,但如果采用血浆进行分析,分析的特异性似乎更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号